Vimarsana
Biggest News Aggregation in the World

Confident Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confident Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confident Interval Today - Breaking & Trending Today

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma - Vimarsana News

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

Published: June 4, 2022

04.06.2022 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, presented today new and updated results from the CARTITUDE ...

Source: wallstreet-online.de
Related Topics:
United StatesNew JerseyHemophagocytic LymphohistiocytosisSaadz UsmaniYing HuangJanssen Biotech IncExchange Commission OnAmerican Society Of Clinical OncologyMyeloma ServiceChinese CenterEuropean Commission For The Treatment Of PatientsAmerican Society Of HematologyAmerican Society Of Clinical Oncology Annual MeetingLegend Biotech CorporationDrug Evaluation Of National Medical Products AdministrationCommunity Register Of Orphan Medicinal ProductsAmerican Cancer SocietyDrug AdministrationEuropean CommissionMedicinal Devices AgencyEuropean Medicines AgencyBiotech IncMemorial Sloan Kettering Cancer CenterConfident IntervalAnnual Meeting
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtag - Vimarsana News

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtag

Published: June 4, 2022

28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meetingOverall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reachedResul...

Source: pharmiweb.com
Related Topics:
United StatesHemophagocytic LymphohistiocytosisSaadz UsmaniJoanne ChoiYing HuangBiotech CorporationJanssen Biotech IncAmerican Society Of Clinical OncologyEuropean CommissionDrug AdministrationMyeloma ServiceMedicinal Devices AgencyAmerican Society Of HematologyLegend Biotech CorporationBiotech IncMemorial Sloan Kettering Cancer CenterLegend BiotechClinical OncologyShow DeepConfident IntervalAnnual MeetingReinforce PotentialChief Executive OfficerJanssen BiotechBreakthrough Therapy Designation